First-line sacituzumab govitecan ups PFS in metastatic TBNC
07 Nov 2025
byElaine Soliven
First-line treatment with sacituzumab govitecan, an antibody drug conjugate, significantly improved progression-free survival (PFS) compared with chemotherapy in patients with metastatic triple-negative breast cancer (TNBC), according to the ASCENT-03 trial presented at ESMO 2025.